AMCP CEO Blog: With PA so often misunderstood, perhaps we need to do a better job of explaining this tool to the general public. For example, we might provide an example of how PAs are applied to opioids as additional safeguards to ensure their appropriate use. Or how a PA might be applied to botulinum toxin to ensure the prescription is for medical, rather than cosmetic, purposes.
By AMCP CEO Susan A. Cantrell, RPh, CAE • 11/13/19
AMCP will occasionally publish highlights from AMCP and other conferences designed for those in managed care pharmacy. Highlights include summaries of select featured session and posters. Meetings published currently include AMCP Nexus 2019, AMCP's 2019 Annual Meeting, and the 2019 ACR/ERP Annual Meeting.
Sponsored webinar that provided an overview of key pharmacist-specific considerations for biosimilars, including details of the approval process, considerations for appropriate use, and practices that mitigate inadvertent substitution and encourage accurate adverse event reporting.